[HTML][HTML] Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate
B Zhang, AC Strauss, S Chu, M Li, Y Ho, KD Shiang… - Cancer cell, 2010 - cell.com
Imatinib mesylate (IM) induces remission in chronic myelogenous leukemia (CML) patients
but does not eliminate leukemia stem cells (LSCs), which remain a potential source of …
but does not eliminate leukemia stem cells (LSCs), which remain a potential source of …
Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate
B Zhang, AC Strauss, S Chu, M Li, YW Ho… - Cancer Cell, 2010 - eprints.gla.ac.uk
Imatinib mesylate (IM) induces remission in chronic myelogenous leukemia (CML) patients
but does not eliminate leukemia stem cells (LSCs), which remain a potential source of …
but does not eliminate leukemia stem cells (LSCs), which remain a potential source of …
[引用][C] Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate.
B Zhang - Cancer Cell, 2010 - cir.nii.ac.jp
Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone
deacetylase inhibitors in combination with imatinib mesylate. | CiNii Research CiNii 国立情報学 …
deacetylase inhibitors in combination with imatinib mesylate. | CiNii Research CiNii 国立情報学 …
Effective Targeting of Quiescent Chronic Myelogenous Leukemia Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate
B Zhang, AC Strauss, S Chu, M Li, Y Ho, KD Shiang… - Cancer Cell, 2010 - infona.pl
Imatinib mesylate (IM) induces remission in chronic myelogenous leukemia (CML) patients
but does not eliminate leukemia stem cells (LSCs), which remain a potential source of …
but does not eliminate leukemia stem cells (LSCs), which remain a potential source of …
[PDF][PDF] Effective Targeting of Quiescent Chronic Myelogenous Leukemia Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate
B Zhang, AC Strauss, S Chu, M Li, Y Ho, KD Shiang… - Cancer Cell, 2010 - academia.edu
Imatinib mesylate (IM) induces remission in chronic myelogenous leukemia (CML) patients
but does not eliminate leukemia stem cells (LSCs), which remain a potential source of …
but does not eliminate leukemia stem cells (LSCs), which remain a potential source of …
Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate.
B Zhang, AC Strauss, S Chu, M Li, Y Ho, KD Shiang… - 2010 - mouseion.jax.org
Imatinib mesylate (IM) induces remission in chronic myelogenous leukemia (CML) patients
but does not eliminate leukemia stem cells (LSCs), which remain a potential source of …
but does not eliminate leukemia stem cells (LSCs), which remain a potential source of …
[HTML][HTML] Effective Targeting of Quiescent Chronic Myelogenous Leukemia Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate
B Zhang, AC Strauss, S Chu, M Li, Y Ho, KD Shiang… - Cancer cell, 2010 - ncbi.nlm.nih.gov
Imatinib mesylate (IM) induces remission in chronic myelogenous leukemia (CML) patients
but does not eliminate leukemia stem cells (LSC), which remain a potential source of …
but does not eliminate leukemia stem cells (LSC), which remain a potential source of …
Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate
B Zhang, AC Strauss, S Chu, M Li, Y Ho… - Cancer …, 2010 - pubmed.ncbi.nlm.nih.gov
Imatinib mesylate (IM) induces remission in chronic myelogenous leukemia (CML) patients
but does not eliminate leukemia stem cells (LSCs), which remain a potential source of …
but does not eliminate leukemia stem cells (LSCs), which remain a potential source of …
[PDF][PDF] Effective Targeting of Quiescent Chronic Myelogenous Leukemia Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate
B Zhang, AC Strauss, S Chu, M Li, Y Ho, KD Shiang… - Cancer Cell, 2010 - core.ac.uk
Imatinib mesylate (IM) induces remission in chronic myelogenous leukemia (CML) patients
but does not eliminate leukemia stem cells (LSCs), which remain a potential source of …
but does not eliminate leukemia stem cells (LSCs), which remain a potential source of …
Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate.
B Zhang, AC Strauss, S Chu, M Li, Y Ho, KD Shiang… - Cancer Cell, 2010 - europepmc.org
Imatinib mesylate (IM) induces remission in chronic myelogenous leukemia (CML) patients
but does not eliminate leukemia stem cells (LSC), which remain a potential source of …
but does not eliminate leukemia stem cells (LSC), which remain a potential source of …